Comparative Study of Vascular Endothelial Growth Factor in Exudative and Transudative Pleural Effusion.
Exudate
Pleural Effusion
Transudate
Vascular Endothelial Growth Factor (VEGF)
Journal
Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
03
07
2021
accepted:
09
02
2022
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
ppublish
Résumé
Increased vascular permeability is one of the main mechanisms in the production of pleural effusion (PE) and vascular endothelial growth factor (VEGF) has a significant role in its pathogenesis. This study aimed to compare pleural levels of VEGF in transudative and exudative PEs besides the other pleural markers. In this prospective cross-sectional study, 80 patients with PE were divided into 4 groups as transudative (N=15), parapneumonic (N=15), tuberculosis (N=25), and malignant (N=25) PE. Biochemical tests measured the pleural protein, LDH, cholesterol, glucose, polymorphonuclear cell (PMN), and lymphocyte. ELISA measured the pleural VEGF level. Out of 80 patients, 51 were male, and the total mean age was 55.34±18.53. There were significant differences in pleural VEGF between exudative and transudative effusion (P<0.001) and between malignant and benign effusion (P=0.014). The highest mean difference in pleural VEGF levels was seen in the comparison of transudative and malignant groups (Mean difference=-136.56; P<0.002). The VEGF level in 3 groups was not significantly different; transudative vs tuberculous, parapneumonic vs tuberculous, and parapneumonic vs malignant. Furthermore, VEGF higher than 73.09 pg/ml had a 64% sensitivity and 82% specificity for the diagnosis of malignancy. Among pleural markers (VEGF, protein, LDH, and glucose), VEGF had the highest area under curve (AUC=0.734). Moreover, pleural protein, LDH, and glucose levels significantly correlated with pleural VEGF; however, pleural cholesterol, PMN, and lymphocyte were not correlated. VEGF is assumed as an important factor in the pathogenesis of exudative PE, especially malignant effusion. It can distinguish between lymphocytic exudative PEs.
Sections du résumé
Background
UNASSIGNED
Increased vascular permeability is one of the main mechanisms in the production of pleural effusion (PE) and vascular endothelial growth factor (VEGF) has a significant role in its pathogenesis. This study aimed to compare pleural levels of VEGF in transudative and exudative PEs besides the other pleural markers.
Materials and Methods
UNASSIGNED
In this prospective cross-sectional study, 80 patients with PE were divided into 4 groups as transudative (N=15), parapneumonic (N=15), tuberculosis (N=25), and malignant (N=25) PE. Biochemical tests measured the pleural protein, LDH, cholesterol, glucose, polymorphonuclear cell (PMN), and lymphocyte. ELISA measured the pleural VEGF level.
Results
UNASSIGNED
Out of 80 patients, 51 were male, and the total mean age was 55.34±18.53. There were significant differences in pleural VEGF between exudative and transudative effusion (P<0.001) and between malignant and benign effusion (P=0.014). The highest mean difference in pleural VEGF levels was seen in the comparison of transudative and malignant groups (Mean difference=-136.56; P<0.002). The VEGF level in 3 groups was not significantly different; transudative vs tuberculous, parapneumonic vs tuberculous, and parapneumonic vs malignant. Furthermore, VEGF higher than 73.09 pg/ml had a 64% sensitivity and 82% specificity for the diagnosis of malignancy. Among pleural markers (VEGF, protein, LDH, and glucose), VEGF had the highest area under curve (AUC=0.734). Moreover, pleural protein, LDH, and glucose levels significantly correlated with pleural VEGF; however, pleural cholesterol, PMN, and lymphocyte were not correlated.
Conclusion
UNASSIGNED
VEGF is assumed as an important factor in the pathogenesis of exudative PE, especially malignant effusion. It can distinguish between lymphocytic exudative PEs.
Types de publication
Journal Article
Langues
eng
Pagination
384-390Informations de copyright
Copyright© 2022 National Research Institute of Tuberculosis and Lung Disease.
Références
FASEB J. 1999 Jan;13(1):9-22
pubmed: 9872925
J Lab Physicians. 2012 Jan;4(1):35-8
pubmed: 22923920
Chin Med J (Engl). 2015 Feb 5;128(3):305-9
pubmed: 25635424
J Clin Pathol. 2002 Jan;55(1):69-71
pubmed: 11825930
Postgrad Med J. 2005 Nov;81(961):702-10
pubmed: 16272233
Interact Cardiovasc Thorac Surg. 2011 Mar;12(3):420-4
pubmed: 21172937
Curr Oncol Rep. 2013 Jun;15(3):207-16
pubmed: 23568600
Tanaffos. 2017;16(2):157-165
pubmed: 29308081
Chin Med J (Engl). 2016 Feb 5;129(3):253-8
pubmed: 26831224
Biomolecules. 2020 Jul 28;10(8):
pubmed: 32731396
Respir Med. 2002 Oct;96(10):817-22
pubmed: 12412982
Tohoku J Exp Med. 2017;242(2):137-142
pubmed: 28626164
Arch Bronconeumol. 2005 Jul;41(7):376-9
pubmed: 16029730
Ann Intern Med. 1972 Oct;77(4):507-13
pubmed: 4642731
Respir Med. 2008 May;102(5):774-9
pubmed: 18304793
BMC Pulm Med. 2014 Apr 15;14:61
pubmed: 24731290
Exp Ther Med. 2010 Jan;1(1):3-7
pubmed: 23136584
J Med Invest. 2007 Feb;54(1-2):146-53
pubmed: 17380026